UNSPSC 51113207: Tretamine or triethylenemelamine

This classification denotes an ethylenimine compound with the molecular formula C9H12N6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F7IY6HZG9D, chemically known as 2,4,6-tris(ethylenimino)-s-triazine but more generally known as tretamine, which bears US NIH Compound Identifier 5799. European Medicines Agency schedules Tretamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11243MIG.

The term TRETAMINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, No. 12, 1959, List 3). TRETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Tretamine or triethylenemelamine bears US NLM identifiers UMLS ID C0040975 and NCI Concept Code C29858. SMILES: N1(CC1)C1NC(N2CC2)NC(N2CC2)N1.

UNSPSC 51113207 Tretamine or triethylenemelamine is a Commodity code nominally covering a specific pharmaceutical chemical compound, but recent state and local procurement activity under this code shows limited direct alignment with the pharmaceutical bulk-chemical scope the code's name suggests. The single recent opportunity on record—Texas Health and Human Services Commission (HHS) Request for Information (RFI) No. HHS0017013, posted April 3, 2026—addresses pharmacy benefit program design and direct-to-manufacturer prescription fulfillment strategy rather than procurement of the chemical itself. The RFI solicits vendor capabilities for establishing direct contracting relationships between state pharmacy programs and pharmaceutical manufacturers to streamline prescription fulfillment and cost management outside traditional pharmacy benefit manager and group purchasing organization channels. Issuing bodies under this code appear limited to state health and human services agencies evaluating pharmacy supply-chain innovation, rather than a broad mix of counties, cities, school districts, or transit authorities.

The geographic spread of recent activity under this code is narrow, with Texas HHS as the sole identifiable recent issuer. The April 2026 RFI represents an exploratory, pre-RFP phase with no formal evaluation criteria, set-aside designations, award values, or binding timelines specified; the state is gathering market intelligence on vendor capabilities to design a future formal solicitation. This code shows minimal recent procurement velocity and may not represent a priority pursuit avenue unless your firm has direct pharmaceutical distribution or manufacturer-direct contracting experience applicable to state health plan programs.